ILSI-Biomed Israel

The Law of the Ordinary and Contact Lenses against Glaucoma

A new invention in the form of contact lenses against glaucoma, shows how biomedical devices should be designed I like to think about biomedical instruments as bits of magic. Not because they cause wonders and provide instant-cures (though some do), but because the more ordinary and mundane in appearance they are, the better they become – much as in magic tricks. It’s the Law of the Ordinary ™. If you market a device for overcoming seizures, and it looks like a robotic arm-sleeve, the...

OrSense Receives FDA Approval for Non-Invasive Oximetry Monitoring System

OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, announced it has received U.S. Food and Drug Administration (FDA) approval for NBM-200MP, a non-invasive oximetry and low signal oximetry sensor.   Non-invasive pulse oximetry has become a standard of care in the operating and recovery rooms, intensive care units and emergency services, yet it has been known to provide erroneous oxygen saturation readings in situations of low perfusion, low...

April 15: Joint Meeting of the European Society of Neuroradiology and the Israel Society of Neuroradiology

מצורפת בזאת ההזמנה לכנס הראשון המשותף לחברה הנוירורדיולוגית הכלל אירופאית ולחברה הישראלית העוסק בדימות מערכת העצבים. esnr-prospect-10_[1] Registration_form.FINAL![1]

ILSI-BioMed Week – the Israeli BioMed Industry's Largest Annual Event

ILSI Biomed Israel 2010: Cutting-edge technological innovations, industry leaders and an abundance of business opportunities -------------------------------------------------------------------------------------------- The Israeli BioMed Industry’s largest annual event is set to be held June 14–16, 2010 in Tel Aviv.  Considered the biggest life sciences conference held outside the USA, ILSI Biomed attracts the world’s leading biotechnology, medicine and medical device entities --------------...

ILSI-BioMed Week – the Israeli BioMed Industry’s Largest Annual Event

ILSI Biomed Israel 2010: Cutting-edge technological innovations, industry leaders and an abundance of business opportunities -------------------------------------------------------------------------------------------- The Israeli BioMed Industry’s largest annual event is set to be held June 14–16, 2010 in Tel Aviv.  Considered the biggest life sciences conference held outside the USA, ILSI Biomed attracts the world’s leading biotechnology, medicine and medical device entities ------...

Shut Down a Gene – Rescue a Limb?

Researchers found out how 'healer' mice regenerate lost digits and articular cartilage. Is there hope for human beings as well? Fourteen years ago, holes were cut into several mice’s ears, to assist in their identification in an immunology experiment. A few weeks later, the experiment failed, since the researchers could not distinguish between the two groups of mice. They have all regenerated their ear tissue, and the holes were long gone, with no scar to show. Ever since that time, these...

April 11: A Course on medical Patents and IP

Tel Aviv University is hosting a course on Medical Patents and IP, starting on April 11. Registration closes March 24. The following is information on a Course on Medical Patents and IP starting on April 11. Registration closes March 24. TEL AVIV UNIVERSITY אוניברסיטת תל- אביב Sackler Faculty of  Medicine School of Continuing Medical EducationRamat Aviv, Tel-Aviv 69978Tel.:03-6409795/7, 03-6409228/9, Fax:03-6409043 הפקולטה לרפואה ע”ש סאקלרבית הספר ללימודי המשך ברפואהרמת אביב...

Protalix Initiates a Phase I Clinical Trial of Acetylcholinesterase for Biodefense Indications

Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX) announced today that it has initiated a phase I clinical trial of PRX-105, the Company's plant cell expressed pegylated recombinant human acetylcholinesterase product candidate in development for biodefense indications. Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX) announced today that it has initiated a phase I clinical trial of PRX-105, the Company's plant cell expressed pegylated recombinant human acetylcholinesterase product candidate ...

Israeli Scientists Discover Genetic Markers of MS

According to The Jerusalem Post, a Israeli team of neurologists discovered signs of MS that appear up to nine years before the onset Multiple sclerosis (MS) is an incredibly damaging disorder, with an average age of onset ranging from the mid-twenties to the mid-thirties. And we have no real cure for it. Teva’s Copaxone is able to slow down the progress of the disease, but it does not halt it in its track. And worst of all, we are still not sure of the cause, and who stands a higher chanc...

Are You Ready for the Future? A Meeting by Wind River

Wind River arranges a meeting regarding business issues and technology trends for medical devices Are you ready for the future? Too bad, because it’s already here. If you want to know exactly where it is, and how to recognize this future when you see it, Wind River offers the chance for executives, project and program managers, to meet together and discuss with the industry experts on the new trends, challenges and solutions they offer. Wind River, in case you haven’t heard yet, is in a very ...